Following the acquisition, inVentiv Health’s clinical segment comprises i3, along with inVentiv’s existing clinical businesses and PharmaNet Development Group.
i3 CEO Glenn Bilawsky said for their clients, this will mean expanded clinical resources and expertise in the US and throughout the world to meet their needs.
"For our employees, it will mean exciting new opportunities to actively participate in building a true company," Bilawsky said.